Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Pieri

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Tumori|November 11, 2003
Redox modulation of NF-kappaB nuclear translocation and DNA binding in metastatic melanoma. The role of endogenous and gamma-glutamyl transferase-dependent oxidative stressSilvia Dominici, Athanase Visvikis, Lisa Pieri, et al.
American Journal of Hematology|January 3, 2014
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion geneClelia Tiziana Storlazzi, Lisa Pieri, Chiara Paoli, et al.
Haematologica|July 18, 2009
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraLisa Pieri, Costanza Bogani, Paola Guglielmelli, et al.
Journal of Clinical Medicine|May 11, 2024
Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single CenterChristian Carulli, Giovanna Daniele, Silvia Linari, et al.
Blood|December 28, 2013
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemiaGiada Rotunno, Carmela Mannarelli, Paola Guglielmelli, et al.
Journal of Clinical Medicine|March 29, 2023
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World ExperienceGiancarlo Castaman, Silvia Linari, Lisa Pieri, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 10, 2025
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half-Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective StudyLuigi Piero Solimeno, Roberta Gualtierotti, Emanuele Guido, et al.
Haematologica|January 2, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemiaElisabetta Antonioli, Paola Guglielmelli, Giada Poli, et al.
Genomics Data|October 21, 2015
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosisChristophe Martinaud, Christophe Desterke, Johanna Konopacki, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 21, 2024
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in ItalyAugusto B Federici, Rita Carlotta Santoro, Cristina Santoro, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Tumori|November 11, 2003
Redox modulation of NF-kappaB nuclear translocation and DNA binding in metastatic melanoma. The role of endogenous and gamma-glutamyl transferase-dependent oxidative stressSilvia Dominici, Athanase Visvikis, Lisa Pieri, et al.
American Journal of Hematology|January 3, 2014
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion geneClelia Tiziana Storlazzi, Lisa Pieri, Chiara Paoli, et al.
Haematologica|July 18, 2009
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraLisa Pieri, Costanza Bogani, Paola Guglielmelli, et al.
Journal of Clinical Medicine|May 11, 2024
Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single CenterChristian Carulli, Giovanna Daniele, Silvia Linari, et al.
Blood|December 28, 2013
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemiaGiada Rotunno, Carmela Mannarelli, Paola Guglielmelli, et al.
Journal of Clinical Medicine|March 29, 2023
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World ExperienceGiancarlo Castaman, Silvia Linari, Lisa Pieri, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 10, 2025
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half-Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective StudyLuigi Piero Solimeno, Roberta Gualtierotti, Emanuele Guido, et al.
Haematologica|January 2, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemiaElisabetta Antonioli, Paola Guglielmelli, Giada Poli, et al.
Genomics Data|October 21, 2015
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosisChristophe Martinaud, Christophe Desterke, Johanna Konopacki, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 21, 2024
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in ItalyAugusto B Federici, Rita Carlotta Santoro, Cristina Santoro, et al.
Pageof 6